Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

To explore the association between bone metastases and the occurrence of severe hematotoxicity, several factors influencing bone metabolism were assessed, including vitamin D supplementation, proton pump inhibitor therapy and bisphosphonate treatment.

Source: 3.4. Hematologic Toxicity and Bone Metastasis. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

PemToxTrial: An Observational Study of PEMetrexed-Associated Severe HematoTOXicity in Lung Adenocarcinoma with Bone Metastases

Source: Article title.

For this analysis, all patients aged ≥18 years with histologically confirmed LUAD treated at the Lung Cancer Center Ulm between 2018 and 2024 were screened (data cut-off 5 November 2024).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

PemToxTrial: An Observational Study of PEMetrexed-Associated Severe HematoTOXicity in Lung Adenocarcinoma with Bone Metastases

Observational study · Cancers · 2026

Original publication title

PemToxTrial: An Observational Study of PEMetrexed-Associated Severe HematoTOXicity in Lung Adenocarcinoma with Bone Metastases

Christian Riedel; Christian Neumann; Raban Heller; Arthur Bauer; Patrick Büchele; Konrad Steinestel; Michael Grunert; Jan Sölter; Niklas Gebauer; Annette Arndt; Matthias Müller; Armin Riecke; Hanno Witte

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Simple Summary

Despite years of use, there is currently no evidence regarding the extent to which bone metastases affect the incidence of side effects during pemetrexed therapy. Based on clinical observations, a retrospective study was conducted to investigate the incidence of severe hematopoietic side effects in patients with lung adenocarcinoma in order to identify patients at risk for these events. In the future, these patients might benefit from a treatment regimen without pemetrexed or from closer monitoring during therapy, in line with a personalized treatment approach.

Abstract

Introduction: Pemetrexed, an antifolate, is a standard therapy for lung adenocarcinoma (LUAD). Since folic acid is vital for nucleic acid metabolism, disrupting its pathway affects both tumor cells and regenerating healthy cells. The PemToxTrial examined the impact of pemetrexed on severe hematotoxicity and mortality. Methods: This retrospective analysis included 136 LUAD patients (UICC8 stage IVA/B) receiving palliative treatment. Ninety-two patients received pemetrexed-based therapy, while 44 received pemetrexed-free treatment (68 and 38 with immune-checkpoint inhibitors). Bone metastasis (BM) was present in 47 patients in the pemetrexed group and 22 in the comparison group.

The primary endpoint was grade III: V hematotoxicity; secondary endpoints included mortality, progression-free survival (PFS), and overall survival (OS). Hematologic outcomes following a subsequent change in clinical practice were prospectively assessed in a post-implementation cohort of 15 patients with bone-metastatic LUAD receiving pemetrexed-free regimens. Results: Median age was 66 years, 59.6% were male and median follow-up was 13.5 months. Grade III-V hematotoxicity was most frequent (81%) in patients with BM receiving pemetrexed (n = 47), significantly higher than in other subgroups (p < 0.0001).

Mortality was also increased in this group (66% vs. 29%, p < 0.0001), with hematotoxicity directly contributing to death in 42% versus 11.5% of cases. PFS was significantly inferior (5.2 vs. 8.6 months). Multivariable analysis identified BM as the only independent predictor of severe hematotoxicity and mortality. Only a mutational burden of ≥4 potential driver alterations was associated with inferior PFS. Bone-derived total lesion glycolysis (TLG) on PET-CT strongly correlated with high-grade hematotoxicity (p < 0.0001). Conclusions: The PemToxTrial identified a strong association between pemetrexed exposure, bone metastases, and severe hematotoxicity, supporting further prospective evaluation of bone metastasis status as a potential clinical risk factor for treatment-associated hematotoxicity.

Authors’ abstract

Simple Summary

Despite years of use, there is currently no evidence regarding the extent to which bone metastases affect the incidence of side effects during pemetrexed therapy. Based on clinical observations, a retrospective study was conducted to investigate the incidence of severe hematopoietic side effects in patients with lung adenocarcinoma in order to identify patients at risk for these events. In the future, these patients might benefit from a treatment regimen without pemetrexed or from closer monitoring during therapy, in line with a personalized treatment approach.

Abstract

Introduction: Pemetrexed, an antifolate, is a standard therapy for lung adenocarcinoma (LUAD). Since folic acid is vital for nucleic acid metabolism, disrupting its pathway affects both tumor cells and regenerating healthy cells. The PemToxTrial examined the impact of pemetrexed on severe hematotoxicity and mortality. Methods: This retrospective analysis included 136 LUAD patients (UICC8 stage IVA/B) receiving palliative treatment. Ninety-two patients received pemetrexed-based therapy, while 44 received pemetrexed-free treatment (68 and 38 with immune-checkpoint inhibitors). Bone metastasis (BM) was present in 47 patients in the pemetrexed group and 22 in the comparison group.

The primary endpoint was grade III: V hematotoxicity; secondary endpoints included mortality, progression-free survival (PFS), and overall survival (OS). Hematologic outcomes following a subsequent change in clinical practice were prospectively assessed in a post-implementation cohort of 15 patients with bone-metastatic LUAD receiving pemetrexed-free regimens. Results: Median age was 66 years, 59.6% were male and median follow-up was 13.5 months. Grade III-V hematotoxicity was most frequent (81%) in patients with BM receiving pemetrexed (n = 47), significantly higher than in other subgroups (p < 0.0001).

Mortality was also increased in this group (66% vs. 29%, p < 0.0001), with hematotoxicity directly contributing to death in 42% versus 11.5% of cases. PFS was significantly inferior (5.2 vs. 8.6 months). Multivariable analysis identified BM as the only independent predictor of severe hematotoxicity and mortality. Only a mutational burden of ≥4 potential driver alterations was associated with inferior PFS. Bone-derived total lesion glycolysis (TLG) on PET-CT strongly correlated with high-grade hematotoxicity (p < 0.0001). Conclusions: The PemToxTrial identified a strong association between pemetrexed exposure, bone metastases, and severe hematotoxicity, supporting further prospective evaluation of bone metastasis status as a potential clinical risk factor for treatment-associated hematotoxicity.

Publication and source details

Original title: PemToxTrial: An Observational Study of PEMetrexed-Associated Severe HematoTOXicity in Lung Adenocarcinoma with Bone Metastases

Christian Riedel; Christian Neumann; Raban Heller; Arthur Bauer; Patrick Büchele; Konrad Steinestel; Michael Grunert; Jan Sölter; Niklas Gebauer; Annette Arndt; Matthias Müller; Armin Riecke; Hanno Witte

Cancers · 2026

* Correspondence: hanno.witte@uni-ulm.de
†

These authors contributed equally to this work.

‡

Shared senior authorship.

© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.German Federal Armed Forces45K3-S-54-2224Parts of this work were financially supported by the special research project (German Federal Armed Forces) 45K3-S-54-2224.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:28:59.458289+00:00

DOI: 10.3390/cancers18203281 · PMC13702182